Life Molecular Imaging
Andrew Stephens has a diverse work experience spanning several companies and roles. Andrew began their career as a student/resident at the University of Colorado Health Sciences Center in 1983. Andrew then worked as a Senior Scientist at NeXagen from 1993 to 1996, followed by an Associate Director role at NeXstar/Gilead Science until 2001. From 2001 to 2003, they served as a Group Leader at Schering AG. Andrew then worked at OSI Pharmaceuticals as a Senior Director from 2003 to 2010. After that, they served as V.P. Experimental Medicine, Oncology/Diagnostic Imaging at Bayer HealthCare from 2010 to 2012. Andrew then joined Piramal Imaging as VP, Clinical Research and Development from 2012 to 2013, and subsequently became their Chief Medical Officer until 2018. Currently, they are working as the Chief Medical Officer at Life Molecular Imaging since 2018.
Andrew Stephens attended Graland from 1964 to 1973 and graduated. Andrew then studied at the University of Colorado Boulder from 1977 to 1980, earning a Bachelor's degree in Chemistry and Philosophy. From 1983 to 1989, they continued their education at the University of Colorado Anschutz Medical Campus, obtaining a MD and a Ph.D. in Biochemistry. Finally, from 1990 to 1993, they completed their medical education at the University of Colorado Anschutz Medical Campus, earning a Doctor of Medicine (M.D.) degree in Internal Medicine.
This person is not in any offices
Life Molecular Imaging
Life Molecular Imaging (formerly Piramal Imaging) is now part of the Alliance Medical Group, an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allow physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine. With an ever increasing demand of effective care as well as a growing global awareness of healthcare efficiency and costs, improved diagnostic tools offer a unique opportunity for: - Earlier detection and better characterization of diseases - Determining the right therapy at the right dose for a patient (precision medicine) - Monitoring therapy response As a global leader in the field of radiopharmaceuticals, Life Molecular Imaging is developing a product portfolio of innovative molecular imaging probes that address major clinical needs in neurology, oncology, and cardiology. Life Molecular Imaging is supporting use of imaging biomarkers in several major therapeutic trials in Alzheimer’s disease. Imprint: Life Molecular Imaging GmbH Tegeler Strasse 6-7 13353 Berlin Germany Telefon: +49 30 461 124603 Fax: +49 30 461 124 629 Email: info@life-mi.com Internet: http://www.life-mi.com Managing Directors: Dr. Ludger Dinkelborg Michel Jongens Chamber of Commerce: Amtsgericht Charlottenburg HRB 136823 B Sales tax identification number: DE 283685037 Data Protection Policy: https://life-mi.com/data-protection/